Objective To study the synergistic effect of STI571, an inhibitor of tyrosine kinase, in
combination with arsenic trioxide As 2 O 3 on a multidrug-resistant leukemia cell line …

Objective To study the synergistic effect of STI571, an inhibitor of tyrosine kinase in
combination with arsenic trioxide (As (2) O (3)) on a multidrug-resistant leukemia cell line …

Purpose: To study new treatment of leukemia with both bcr-abl and mdrl positive. Methods:
We detected the effect of STI571 (1? mol/L), an inhibitor of tyrosine kinase, in combination …

Objective To study the effects of STI571, arsenic trioxide (As2O3) and Velcade, used alone
or in combination, on the proliferation and apoptosis of bcr/abl+-CD34+ cells. Methods …

This study was aimed to explore the effects of STI571 alone or with As₂O₃ on proliferation,
apoptosis and caspase 3, bcl-xL mRNA expression of K562 cells, and the molecular …

Background The development of the targeted signal transduction inhibitor STI571 has
prompted us to treat chronic myeloid leukemia in different ways. Since STI571 may reverse …

By inhibiting the tyrosine kinase (TK) activity of Bcr-Abl, STI-571 induces differentiation and
apoptosis of HL-60/Bcr-Abl (with ectopic expression of p185 Bcr-Abl) and K562 (containing …

To explore the possibility of leukemia cell line of both bcr-abl and mdr-1 positive were cross-
resistant to tyrosine kinase inhibitor STI571 and its reversal way, the inhibitory effect of …

To produce leukemic STI571-resistant cell lines and to explore the molecular mechanism of
STI571-resistance, cell lines K562-n and K562-n/VCR were induced by exposing cells to …

Purpose To study the apoptotic effect of the 2-phenylaminopyrimidine derivative STI571 in
combination with antioxidant agents on K-562 cell line derived from a Philadelphia …